Tanja Falter1,2, Veronique Schmitt1, Stephanie Herold1, Veronika Weyer3, Charis von Auer4, Stefanie Wagner5, Gudrun Hefner1,5, Manfred Beutel6, Karl Lackner1, Bernhard Lämmle2,7, Inge Scharrer4. 1. Institute of Clinical Chemistry and Laboratory Medicine. 2. Center for Thrombosis and Hemostasis (CTH). 3. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI). 4. Department of Hematology, Oncology and Pneumology. 5. Department of Psychiatry and Psychotherapy. 6. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. 7. University Clinic of Hematology & Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital, Bern, Switzerland.
Abstract
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor-induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS: The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (IDS-SR) and mental performance (FLei). We received answers of 104 individual TTP patients and 55 of them participated in both surveys. RESULTS: Seventy-one of the 104 responding TTP patients (68%) suffered from depression and the severity of depression was similar in both surveys performed 1 year apart. Furthermore, TTP patients had considerably lower cognitive performance than controls. There was no correlation between prevalence of depression and cognitive deficits and the number and the severity of acute episodes. Impairment of mental performance correlated with the severity of depression (rs = 0.779). CONCLUSION: The prevalence of depression and cognitive deficits was significantly higher in TTP patients. Cognitive impairment seemed to be a consequence of depression, almost independently of number and severity of TTP episodes.
BACKGROUND:Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor-induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS: The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (IDS-SR) and mental performance (FLei). We received answers of 104 individual TTP patients and 55 of them participated in both surveys. RESULTS: Seventy-one of the 104 responding TTP patients (68%) suffered from depression and the severity of depression was similar in both surveys performed 1 year apart. Furthermore, TTP patients had considerably lower cognitive performance than controls. There was no correlation between prevalence of depression and cognitive deficits and the number and the severity of acute episodes. Impairment of mental performance correlated with the severity of depression (rs = 0.779). CONCLUSION: The prevalence of depression and cognitive deficits was significantly higher in TTP patients. Cognitive impairment seemed to be a consequence of depression, almost independently of number and severity of TTP episodes.
Authors: Max A Brodsky; Senthil Sukumar; Sruthi Selvakumar; Lisa Yanek; Sarah Hussain; Marshall A Mazepa; Evan M Braunstein; Alison R Moliterno; Thomas S Kickler; Robert A Brodsky; Spero R Cataland; Shruti Chaturvedi Journal: Am J Hematol Date: 2021-09-15 Impact factor: 10.047
Authors: Jenna Brown; Bindu Potugari; Marshall A Mazepa; Ruhail Kohli; Alison R Moliterno; Robert A Brodsky; Jason A Vaught; Richard Burwick; Shruti Chaturvedi Journal: Ann Hematol Date: 2022-08-06 Impact factor: 4.030
Authors: Wolfgang Miesbach; Jan Menne; Martin Bommer; Ulf Schönermarck; Thorsten Feldkamp; Martin Nitschke; Timm H Westhoff; Felix S Seibert; Rainer Woitas; Rui Sousa; Michael Wolf; Stefan Walzer; Björn Schwander Journal: Orphanet J Rare Dis Date: 2019-11-15 Impact factor: 4.123
Authors: Hendrika A van Dorland; Magnus Mansouri Taleghani; Kazuya Sakai; Kenneth D Friedman; James N George; Ingrid Hrachovinova; Paul N Knöbl; Anne Sophie von Krogh; Reinhard Schneppenheim; Isabella Aebi-Huber; Lukas Bütikofer; Carlo R Largiadèr; Zuzana Cermakova; Koichi Kokame; Toshiyuki Miyata; Hideo Yagi; Deirdra R Terrell; Sara K Vesely; Masanori Matsumoto; Bernhard Lämmle; Yoshihiro Fujimura; Johanna A Kremer Hovinga Journal: Haematologica Date: 2019-02-21 Impact factor: 9.941
Authors: Shih-Han Susan Huang; Katerina Pavenski; Ting-Yim Lee; Michael T Jurkiewicz; Aditya Bharatha; Jonathan Dale Thiessen; Keith St Lawrence; Jean Théberge; Jennifer Mandzia; David Barth; Christoph Licht; Christopher Jordan Patriquin Journal: Blood Adv Date: 2021-10-26